Previous Close | 0.3400 |
Open | 0.3100 |
Bid | 0.0000 |
Ask | 0.0000 |
Strike | 80.00 |
Expire Date | 2024-01-19 |
Day's Range | 0.3100 - 0.3400 |
Contract Range | N/A |
Volume | |
Open Interest | N/A |
J&J (JNJ) meets the primary goal in the late-stage study of the combination therapy of Rybrevant and lazertinib against Tagrisso for EGFR-mutated first-line NSCLC.
AstraZeneca's (AZN) key drugs like Lynparza, Tagrisso, Fasenra and Farxiga should keep driving revenues. Its pipeline is strong, with several phase III data readouts lined up.
Despite slowing COVID-19 vaccine sales these healthcare titans are trading at more reasonable valuations with a lot of the risk-to-reward being priced into their stocks considering their earnings potential.